08/02/22 8:30 AMNasdaq : NRSN low floatNeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study- NeuroSense's support will aid EverythingALS with ground-breaking patient research in a joint effort to develop treatments- NeuroSense's CEO to present at EverythingALS's Expert Talk Series on August 3, 2022; To listen to Mr. Ben-Noon's presentation register here: LINKLOS ALTOS, Calif. andRHEA-AIpositive
07/28/22 9:00 AMNasdaq : NRSN low floatNeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers Using AI and MLNeuraLight's platform technology uses computer vision, artificial intelligence (AI), deep learning algorithms, and machine learning (ML) to identify and track oculometric digital biomarkers to transform clinical development, diagnostics, and precision medicine in neurology The NeuroSense-NeuraLightRHEA-AIvery positive
07/18/22 8:30 AMNasdaq : NRSN low floatNeuroSense Therapeutics CEO Provides Key Corporate Update VideoNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today released a corporate update video from its Founder and CEO AlonRHEA-AIneutral
07/12/22 5:00 AMNasdaq : CHMA, NRSN managementSpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive OfficerSpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer. Mark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as...RHEA-AIneutral
06/30/22 8:30 AMNasdaq : NRSN low floatNeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker StudyNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatmentsRHEA-AIneutral
06/27/22 8:30 AMNasdaq : NRSN low floatNeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker StudyPreliminary results show levels of disease-related biomarkers remain unchanged in people living with ALS who are treated with standard of care, in contrast to the statistically significant decline in these biomarkers in patients treated in NeuroSense's Phase IIa study with PrimeC New biomarker dataRHEA-AIneutral
06/22/22 8:30 AMNasdaq : NRSN low floatNeuroSense CEO to be Panelist at Maxim Group's Innovations in ALS: Exploring New Treatments In Development on June 28, 2022NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the Company will participate in Maxim Group's panel discussion on Innovations in ALS: Exploring NewRHEA-AIneutral
06/01/22 8:30 AMNasdaq : NRSN low floatNeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeCRHEA-AIvery positive
05/31/22 8:30 AMNasdaq : NRSN earningslow floatNeuroSense Announces First Quarter 2022 Financial Results and Provides Business UpdateNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today reported its financial results for the quarter ended March 31, 2022 and provided a business update.BusinessRHEA-AIneutral
05/23/22 8:30 AMNasdaq : NRSN conferenceslow floatNeuroSense Therapeutics to Present at the ALS Drug Development Summit in Boston on May 26, 2022NeuroSenseRHEA-AIvery positive